Mutation analysis of the hCHK2 gene in primary human malignant gliomas

@article{Louis2000MutationAO,
  title={Mutation analysis of the hCHK2 gene in primary human malignant gliomas},
  author={D. Louis and Y. Ino and D. Wahrer and D. Bell and D. Haber},
  journal={Neurogenetics},
  year={2000},
  volume={3},
  pages={45-46}
}
Sirs, Approximately 30% of human malignant gliomas display allelic loss of 22q, with deletion mapping suggesting the presence of multiple tumor suppressor candidate regions [1]. hCHK2 is a human homologue of the yeast Rad53 gene, which plays a role in control of the G2-M cell cycle checkpoint. The hCHK2 gene maps to 22q11, and is mutated in the germline of some Li-Fraumeni syndrome families, including patients with malignant gliomas [2]. hCHK2 therefore represents a particularly attractive… Expand
Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma
TLDR
Information from the nearly finished physical sequence of chromosome 22 was used to map LOH data from 22q deletion studies on different tumor entities to identify potential tumor suppressor gene candidate regions and two regions were identified on the physical DNA sequence. Expand
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors
TLDR
Findings of CHK2 gene mutations are consistent with osteosarcoma being a defining tumor of Li‐Fraumeni syndrome and emphasizes the importance of the stress pathway which includes TP53. Expand
DNA damage response genes and chromosome 11q21-q24 candidate tumor suppressor genes in breast cancer
TLDR
The only observed CHK2 alteration with a putative effect on cancer susceptibility, Ile157Thr, segregated ambiguously with the disease, and was also present in cancer-free controls, which suggests that together with LOH, methylation could result in biallelic inactivation of the TSLC1 gene in breast cancer. Expand
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer
TLDR
The genomic areas covering TP53, CDKN2A, MLH1, and MSH2 were selected because these genes have been previously reported to be associated with cancer pedigrees known to include glioma. Expand
Rarity of germline 1100delC mutation in CHK2 in patients with malignant melanoma of the skin
TLDR
It seems that examination of sporadic or familial MM cases for the 1100delC germline mutation in CHK2 is not justified, and more MM cases from LFS families should be examined. Expand
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas.
TLDR
Evidence is presented that the DDR exerts tumor suppressor activity in gliomas and that genes encoding components of the DDR pathway are frequently altered in human gliomers and that loss of elements of the ATM/Chk2/p53 cascade accelerates tumor formation in a glioma mouse model. Expand
A robust method for detecting CHK2/RAD53 mutations in genomic DNA
TLDR
A strategy, based on long‐range PCR, to screen the functional copy of CHK2, and it is possible to carry out a comprehensive mutational analysis ofCHK2 from genomic DNA. Expand
CHEK2 ∗1100delC Mutation and Risk of Prostate Cancer
TLDR
An overview of the current knowledge of the role of a genetic variant, 1100delC, of CHEK2 on prostate cancer risk is provided and the implication for potential translation of this knowledge into clinical practice is discussed. Expand
VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKERIN GLIOBLASTOMA MULTIFORME
TLDR
The data suggest that a CHEK2 gene polymorphism might correlate with the prognosis of glioblastoma patients, and may point to an as yet unrecognized role for the CHEk2 gene in gliOBlastomas. Expand
VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME
TLDR
The data suggest that a CHEK2 gene polymorphism might correlate with the prognosis of glioblastoma patients, and may point to an as yet unrecognized role for the CHEk2 gene in gliOBlastomas. Expand
...
1
2
3
...

References

SHOWING 1-4 OF 4 REFERENCES
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
TLDR
HCHK2 is a tumor suppressor gene conferring predisposition to sarcoma, breast cancer, and brain tumors, and the central role of p53 inactivation in human cancer and the well-defined G2 checkpoint in yeast is provided. Expand
Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade.
TLDR
Deletes were performed on 141 tumors using 16 chromosome 22q microsatellite markers to define the most likely location for a putative tumor suppressor gene, raising the possibility that the distal locus is involved in a later stage of astrocytoma tumorigenesis. Expand
Molecular biology of central nervous system tumors.
  • S. Rempel
  • Medicine
  • Current opinion in oncology
  • 1998
TLDR
This review focuses on the known or implicated genetic alterations and their contribution to normal biologic processes hijacked by tumor cells to promote tumor proliferation, invasion, and neovascularity. Expand
Comparative study of p 53 gene and protein alterations in human astrocytomas
  • J Neuropathol Exp Neurol
  • 1993